de Carvalho Gisela Maria Vieira Rodrigues, Nakamura Mary Uchiyama, Simões Ricardo Santos, Antonio Eliana Maria Restum, Wagngner Adriana, Fontes Tereza Maria Pereira, Kulay Júnior Luiz
Departamento de Obstetrícia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.
Rev Bras Ginecol Obstet. 2011 May;33(5):225-30.
To evaluate the effect of administration of a stavudine/nelfinavir combination on the rat pregnancy by assessing maternal and concepts weights, as well as the number of implantations, fetuses, placentas, resorptions and maternal and fetal mortality.
Forty adult pregnant Wistar rats of the EPM-1 strain were randomly divided into four groups: control (GCtrl--drug vehicle control, n=10), and three experimental groups, which were treated with an oral solution of stavudine/nelfinavir (ExpI--1/40 mg/kg b.w., n=10; ExpII--3/120 mg/kg b.w., n=10; ExpIII--9/360 mg/kg b.w., n=10) from day 0 to the 20th day of pregnancy. Maternal body weights were determined at the start of the experiment and on the 7th, 14th and the 20th day thereafter. At term (20th day) the rats were anesthetized and, upon laparotomy and hysterotomy, the number of implantations, resorptions, living fetuses, placentae and intrauterine deaths were recorded. The collected fetuses and placentae were weighed and the concepts were examined under a stereomicroscope for possible external malformations. Statistical analysis was performed by analysis of variance (ANOVA) complemented by the Kruskal-Wallis test (p<0.05).
There was a progressive and gradual increase in body weight during the course of pregnancy in all groups, which was more evident in the final period, but with no significant difference between groups. The mean number of fetuses, placentas, implantations, and fetal and placental weights showed no significant differences between groups. Also, no resorptions or external malformations were found in the experimental groups. However, between the 8th and 14th days of gestation, there was one case of maternal mortality in each experimental group.
The administration of a stavudine/nelfinavir combination had no deleterious effects on the concepts.
通过评估母体和胚胎体重、着床数、胎儿数、胎盘数、吸收数以及母体和胎儿死亡率，来评价司他夫定/奈非那韦联合用药对大鼠妊娠的影响。
将40只EPM-1品系的成年妊娠Wistar大鼠随机分为四组：对照组（GCtrl - 药物赋形剂对照组，n = 10），以及三个实验组，从妊娠第0天至第20天用司他夫定/奈非那韦口服溶液进行治疗（实验组I - 1/40 mg/kg体重，n = 10；实验组II - 3/120 mg/kg体重，n = 10；实验组III - 9/360 mg/kg体重，n = 10）。在实验开始时以及此后的第7天、第14天和第20天测定母体体重。足月时（第20天），将大鼠麻醉，剖腹并切开子宫后，记录着床数、吸收数、存活胎儿数、胎盘数和宫内死亡数。对收集的胎儿和胎盘进行称重，并在体视显微镜下检查胚胎是否存在可能的外部畸形。采用方差分析（ANOVA）并辅以Kruskal-Wallis检验进行统计分析（p<0.05）。
所有组在妊娠期间体重均呈逐渐递增趋势，在妊娠后期更为明显，但各组之间无显著差异。胎儿、胎盘、着床的平均数量以及胎儿和胎盘重量在各组之间无显著差异。此外，实验组未发现吸收或外部畸形。然而，在妊娠第8天至第14天期间，每个实验组均有1例母体死亡。
司他夫定/奈非那韦联合用药对胚胎无有害影响。
